Robert W. Baird restated their buy rating on shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) in a research report sent to investors on Friday. They currently have a $30.00 price objective on the stock.
Separately, Zacks Investment Research downgraded Jounce Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 11th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $23.67.
Shares of Jounce Therapeutics (NASDAQ JNCE) opened at $14.81 on Friday. Jounce Therapeutics has a 1-year low of $11.05 and a 1-year high of $29.29.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thestockobserver.com/2017/11/14/jounce-therapeutics-jnce-buy-rating-reaffirmed-at-robert-w-baird.html.
A number of hedge funds have recently modified their holdings of the business. Teachers Advisors LLC increased its holdings in Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares in the last quarter. Strs Ohio increased its holdings in Jounce Therapeutics by 10.7% in the third quarter. Strs Ohio now owns 41,300 shares of the company’s stock worth $643,000 after purchasing an additional 4,000 shares in the last quarter. American International Group Inc. increased its holdings in Jounce Therapeutics by 132.2% in the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after purchasing an additional 5,442 shares in the last quarter. OxFORD Asset Management LLP increased its holdings in Jounce Therapeutics by 11.9% in the third quarter. OxFORD Asset Management LLP now owns 59,540 shares of the company’s stock worth $927,000 after purchasing an additional 6,328 shares in the last quarter. Finally, Macquarie Group Ltd. bought a new stake in shares of Jounce Therapeutics during the third quarter valued at approximately $124,000. Institutional investors and hedge funds own 44.47% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.